Evidence map›Paper›PMID 37624484›Full record

ArticleJournal of endocrinological investigation2024

Association of tyrosine hydroxylase 01 (TH01) microsatellite and insulin gene (INS) variable number of tandem repeat (VNTR) with type 2 diabetes and fasting insulin secretion in Mexican population.

J Berumen, L Orozco, H Gallardo-Rincón, E Juárez-Torres, E Barrera, M Cruz-López, R E Benuto, E Ramos-Martinez, M Marin-Madina, A Alvarado-Silva and 9 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of endocrinological investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 3 countries.

J BerumenFacultad de Medicina, Unidad de Investigación en Medicina Experimental, Universidad Nacional Autónoma de México, 06720, Mexico City, México. jaimeberumen47@gmail.com.ORCID http://orcid.org/0000-0001-6707-3317
L OrozcoLaboratorio de Inmunogenómica y Enfermedades Metabólicas, Instituto Nacional de Medicina Genómica, Secretaria de Salud, 14610, Mexico City, México.ORCID http://orcid.org/0000-0002-5801-9180
H Gallardo-RincónDepartamento de Soluciones Operativas, Fundación Carlos Slim, 11529, Mexico City, Mexico. hgallardo@fundacioncarlosslim.org.ORCID http://orcid.org/0000-0002-0811-4606
E Juárez-TorresLaboratorio Huella Génica, Unidad de Diabetes, 06600, Mexico City, Mexico.
E BarreraFacultad de Medicina, Unidad de Investigación en Medicina Experimental, Universidad Nacional Autónoma de México, 06720, Mexico City, México.
M Cruz-LópezUnidad de Investigación Médica en Bioquímica, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, 06720, Mexico City, México.ORCID http://orcid.org/0000-0001-9985-6172
R E BenutoLaboratorio Huella Génica, Unidad de Diabetes, 06600, Mexico City, Mexico.
E Ramos-MartinezFacultad de Medicina, Unidad de Investigación en Medicina Experimental, Universidad Nacional Autónoma de México, 06720, Mexico City, México.ORCID http://orcid.org/0000-0002-4361-821X
M Marin-MadinaLaboratorio Huella Génica, Unidad de Diabetes, 06600, Mexico City, Mexico.
A Alvarado-SilvaLaboratorio Huella Génica, Unidad de Diabetes, 06600, Mexico City, Mexico.
A Valladares-SalgadoUnidad de Investigación Médica en Bioquímica, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, 06720, Mexico City, México.
J J Peralta-RomeroUnidad de Investigación Médica en Bioquímica, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, 06720, Mexico City, México.ORCID http://orcid.org/0000-0001-5426-5555
H García-OrtizLaboratorio de Inmunogenómica y Enfermedades Metabólicas, Instituto Nacional de Medicina Genómica, Secretaria de Salud, 14610, Mexico City, México.ORCID http://orcid.org/0000-0002-0453-980X
L A Martinez-JuarezDepartamento de Soluciones Operativas, Fundación Carlos Slim, 11529, Mexico City, Mexico.ORCID http://orcid.org/0000-0001-7550-7867
A MontoyaDepartamento de Soluciones Operativas, Fundación Carlos Slim, 11529, Mexico City, Mexico.
D A Alvarez-HernándezDepartamento de Soluciones Operativas, Fundación Carlos Slim, 11529, Mexico City, Mexico.ORCID http://orcid.org/0000-0003-2340-6639
J Alegre-DiazFacultad de Medicina, Unidad de Investigación en Medicina Experimental, Universidad Nacional Autónoma de México, 06720, Mexico City, México.ORCID http://orcid.org/0000-0001-9390-3871
P Kuri-MoralesProyecto OriGen, Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, México.ORCID http://orcid.org/0000-0002-0704-9507
R Tapia-ConyerFacultad de Medicina, Universidad Nacional Autónoma de México, Coyoacán, 04510, Mexico City, México.ORCID http://orcid.org/0000-0001-9425-7322
Universidad Nacional Autónoma de México · MXMexican Social Security Institute · MXSecretaria de Salud · MXJohns Hopkins University · USTecnológico de Monterrey · MXUniversidad de Guadalajara · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeA variable number of tandem repeats (VNTR) in the insulin gene (INS) control region may be involved in type 2 diabetes (T2D). The TH01 microsatellite is near INS and may regulate it. We investigated whether the TH01 microsatellite and INS VNTR, assessed via the surrogate marker single nucleotide polymorphism rs689, are associated with T2D and serum insulin levels in a Mexican population.

methodsWe analyzed a main case-control study (n = 1986) that used univariate and multivariate logistic regression models to calculate the risk conferred by TH01 and rs689 loci for T2D development; rs689 results were replicated in other case-control (n = 1188) and cross-sectional (n = 1914) studies.

resultsTH01 alleles 6, 8, 9, and 9.3 and allele A of rs689 were independently associated with T2D, with differences between sex and age at diagnosis. TH01 alleles with ≥ 8 repeats conferred an increased risk for T2D in males compared with ≤ 7 repeats (odds ratio, ≥ 1.46; 95% confidence interval, 1.1-1.95). In females, larger alleles conferred a 1.5-fold higher risk for T2D when diagnosed ≥ 46 years but conferred protection when diagnosed ≤ 45 years. Similarly, rs689 allele A was associated with T2D in these groups. In males, larger TH01 alleles and the rs689 A allele were associated with a significant decrease in median fasting plasma insulin concentration with age in T2D cases; the reverse occurred in controls.

conclusionLarger TH01 alleles and rs689 A allele may potentiate insulin synthesis in males without T2D, a process disabled in those with T2D.

Indexed as

Diabetes Mellitus, Type 2Tyrosine 3-MonooxygenaseCase-Control StudiesCross-Sectional StudiesFastingFemaleHumansInsulinInsulin SecretionMaleMicrosatellite RepeatsMinisatellite RepeatsInsulinTyrosine 3-MonooxygenaseDiabetesINSInsulinrs689TH01

Identifiers

PMID37624484
PMCPMC10904573
OpenAlexW4386153997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.